News and Press Releases 2009

December 2, 2009
Takeda to Continue Strategic Expansion with Operations in Brazil
November 2, 2009
Amylin Pharmaceuticals and Takeda Enter into Worldwide Agreement to Co-Develop and Commercialize Compounds for Obesity
October 26, 2009
New Study Results Analyzed the Use of KAPIDEX™ (dexlansoprazole) for Nighttime Heartburn in Adults with Non-Erosive GERD
October 14, 2009
New Data Showed Type 2 Diabetes Patients Experienced Greater Blood Sugar Reductions when Treated with ACTOplus met® (pioglitazone HCl and metformin HCl) as Initial Therapy Compared to Either Component Alone
October 1, 2009
Takeda to Establish Four Sales and Marketing Subsidiaries to Expand its Operations in Mexico, Turkey and Five Other Countries in Europe
September 4, 2009
Takeda Receives FDA Complete Response Letter for the Investigational Fixed-Dose Combination of alogliptin and ACTOS® (pioglitazone HCl) for the Treatment of Type 2 Diabetes
August 28, 2009
Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin, An Investigational Treatment for Type 2 Diabetes
July 22, 2009
Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS® (pioglitazone HCl)
June 26, 2009
Takeda Receives FDA Complete Response Letter for Alogliptin, An Investigational Treatment for Type 2 Diabetes
May 13, 2009
FDA Approves ACTOplus met® XR (pioglitazone HCl and metformin HCl extended-release) Tablets for the Treatment of Type 2 Diabetes
March 31, 2009
Takeda to Create Global Centers of Excellence
March 12, 2009
ULORIC® (febuxostat) 40-mg and 80-mg Tablets Now Available for the Chronic Management of Hyperuricemia in Patients with Gout
February 23, 2009
KAPIDEX™ (dexlansoprazole) delayed release capsules Now Available for the Treatment of GERD
February 13, 2009
FDA Approves ULORIC® (febuxostat) for the Chronic Management of Hyperuricemia in Patients with Gout
January 30, 2009
FDA Approves KAPIDEX™ (dexlansoprazole) delayed release capsules for the Treatment of GERD
January 19, 2009
Review of Takeda’s Febuxostat New Drug Application Continues Past PDUFA Date

Page Top